Here's why this broker rates Clinuvel Pharmaceuticals shares a buy

A broker has rated Clinuvel Pharmaceuticals Limited (ASX: CUV) a Buy, with a price target more than 55% above its current share price.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Broker Moelis Australia has rated Clinuvel Pharmaceuticals Limited (ASX: CUV) a 'buy' with a price target of $44.42.

Clinuvel is a biopharmaceutical company focused on developing treatments for genetic and skin disorders and Clinuvel shares are currently trading at a price of $29.19 per share.

The product

Currently Clinuvel has one product on the market, Scenesse, which is used to treat a rare metabolic disorder, erythropoietic protoporphyria (EPP). EPP causes severe phototoxic reactions to sunlight. Scenesse was approved in the European Union (EU) to treat EPP several years ago and was approved in the United States (US) in October. Clinuvel submitted an application to the TGA for Scenesse to be registered in Australia in December.

Financial results 

Clinuvel delivered a return on equity of 27.97% in FY17, 32.3% in FY18, and 31.57% in FY19. In FY19, Clinuvel revenues increased nearly 22% to $31.02 million, while expenses rose only 8% year on year. Net profit before tax increased 40% to $14.38 million, and basic earnings per share of 37.6 cents were recorded, up 35.7%. Clinuvel declared its maiden dividend in FY19 and paid total dividends of 4.5 cents a share in 2019, unfranked. 

Addressable market 

The company reports that its rollout of Scenesse in EU markets is progressing in line with expectations, with uptake continuing to grow. Moelis Australia sees potential upside in the medium term should the European Medicines Agency relax the maximum 4 doses per annum. Preparations for launch in the US are underway, with Clinuvel engaged in discussions with US insurers and in the process of setting up a US office. First US sales are expected in 2H21. 

Forecast

Moelis Australia is forecasting net profits after tax of $12.1 million in 2020, $15.4 million in 2021, and $25.6 million in 2022 for Clinuvel. Earnings per share are expected to be 23.9 cents, 30.5 cents, and 50.8 cents in each year. The broker predicts Clinuvel will pay dividends of 2.5 cents per share in 2020, 2.9 cents in 2021, and 4.4 cents in 2022. Moelis notes that potential upside could come from faster than expected ramp up in the EU and the US and any success expanding into new indications.  

Potential new products

Successful regulatory approval of Scenesse will likely increase the probability of approvals for new indications of the drug. Clinuvel has announced an intention to develop a product targeting the prevention of skin cancer using the drug. Additional potential applications could provide potential upside. 

Foolish takeaway 

Clinuvel has a unique product and is expanding its market footprint. There is potential for the drug to be applied in new applications in future, which would open up new markets.

The Clinuvel share price is up 3.58% this morning on the news, currently trading for $29.19 per share.

Motley Fool contributor Kate O'Brien has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
Broker Notes

Invest $1,000 into Pilbara Minerals and these ASX 200 stocks

Analysts have named these shares as top picks for a $1,000 investment. Let's see why.

Read more »

Happy young couple saving money in piggy bank.
Opinions

Want to start investing in ASX shares? Here's what I'd buy

This is where I’d begin to put my money in the stock market.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Broker Notes

3 of the best ASX 200 shares to buy in 2025

Let's see why analysts at Bell Potter are bullish on these shares next year.

Read more »

People of different ethnicities in a room taking a big selfie, symbolising diversification.
Opinions

Want diversification? Get it instantly with these ASX 200 shares

Some businesses offer a lot more diversification than others.

Read more »

A happy man and woman on a computer at Christmas, indicating a positive trend for retail shares.
Opinions

2 ASX 200 shares I'd want to receive as a present today

Merry Christmas! Are there any stocks under your tree?

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Avita Medical, GenusPlus, Mesoblast, and Polynovo shares are storming higher

These shares are having a better day than most today. But why?

Read more »

Three guys in shirts and ties give the thumbs down.
Share Fallers

Why Charter Hall Retail, DroneShield, FBR, and St Barbara shares are tumbling today

These shares are having a tough time on Tuesday. But why?

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these stocks.

Read more »